DK0895538T3 - Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter - Google Patents

Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter

Info

Publication number
DK0895538T3
DK0895538T3 DK97921247T DK97921247T DK0895538T3 DK 0895538 T3 DK0895538 T3 DK 0895538T3 DK 97921247 T DK97921247 T DK 97921247T DK 97921247 T DK97921247 T DK 97921247T DK 0895538 T3 DK0895538 T3 DK 0895538T3
Authority
DK
Denmark
Prior art keywords
lymphocytes
ras
identified
mutated ras
produce cytotoxic
Prior art date
Application number
DK97921247T
Other languages
English (en)
Inventor
Jeffrey Schlom
Scott Abrams
Original Assignee
Us Gov Sec Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Sec Health filed Critical Us Gov Sec Health
Application granted granted Critical
Publication of DK0895538T3 publication Critical patent/DK0895538T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464454—Enzymes
    • A61K39/464464—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK97921247T 1996-04-19 1997-04-17 Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter DK0895538T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63534496A 1996-04-19 1996-04-19
PCT/US1997/006470 WO1997040156A1 (en) 1996-04-19 1997-04-17 Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes

Publications (1)

Publication Number Publication Date
DK0895538T3 true DK0895538T3 (da) 2002-11-04

Family

ID=24547410

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97921247T DK0895538T3 (da) 1996-04-19 1997-04-17 Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter

Country Status (8)

Country Link
US (1) US8883448B2 (da)
EP (1) EP0895538B1 (da)
AT (1) ATE220718T1 (da)
AU (1) AU2734397A (da)
DE (1) DE69714033T2 (da)
DK (1) DK0895538T3 (da)
ES (1) ES2180045T3 (da)
WO (1) WO1997040156A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
US6558671B1 (en) 1997-01-30 2003-05-06 The University Of Virginia Patent Foundation Cysteine-depleted peptides recognized by A3-restricted cytotoxic lymphocytes, and uses therefor
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
GB9907860D0 (en) * 1999-04-07 1999-06-02 Smithkline Beecham Biolog Novel compounds
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
WO2004058157A2 (en) 2002-12-16 2004-07-15 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
DK2714071T3 (da) * 2011-05-24 2019-09-16 Biontech Rna Pharmaceuticals Gmbh Individualiserede vacciner mod cancer
WO2013167136A1 (en) 2012-05-08 2013-11-14 Herlev Hospital Improving adoptive cell therapy with interferon gamma
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
CN107075479A (zh) * 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
MA52435A (fr) * 2018-03-02 2021-01-06 Elicio Therapeutics Inc Composés contenant une séquence kras mutante et un lipide et leurs utilisations
EP3914270A4 (en) * 2019-01-25 2023-01-11 The Trustees of the University of Pennsylvania COMPOSITIONS AND METHODS FOR TARGETING MUTANT RAS
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6146633A (en) * 1973-05-07 2000-11-14 The Ohio State University Method for treatment of antigenically modified polypeptides
US5643565A (en) * 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
ATE109008T1 (de) 1988-02-01 1994-08-15 Praxis Biolog Inc T-zellen-epitope als träger für einen konjugierten impfstoff.
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5861372A (en) * 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use

Also Published As

Publication number Publication date
DE69714033D1 (de) 2002-08-22
ATE220718T1 (de) 2002-08-15
EP0895538B1 (en) 2002-07-17
AU2734397A (en) 1997-11-12
DE69714033T2 (de) 2003-02-13
EP0895538A1 (en) 1999-02-10
ES2180045T3 (es) 2003-02-01
WO1997040156A1 (en) 1997-10-30
US20100074945A1 (en) 2010-03-25
US8883448B2 (en) 2014-11-11

Similar Documents

Publication Publication Date Title
DK0895538T3 (da) Muterede ras-peptider til frembringelse af cytotoksiske CD8+-T-lymfocytter
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
DE69733610D1 (de) Interleukin-15 antagoniste
ATE359817T1 (de) Auf n-formyl methionyl peptide basierendem adjuvans für impfstoffe
DE3879062D1 (de) Ergonomischer stuhl.
NO974258D0 (no) IL-17-reseptor
DE69229428D1 (de) Therapeutisch nützliche peptide und peptidfragmente
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
ES2187946T3 (es) Uso de interleucina-15.
WO1997035021A3 (en) Prostate specific antigen oligo-epitope peptide
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
DE3860354D1 (de) Neigungseinstell- und verstellvorrichtung fuer klapp-, lehnstuehle und aehnliche gegenstaende.
DE3889111D1 (de) Verstellbarer stuhl.
BR0107547A (pt) Receptor
FR2856598A1 (fr) Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
IT1303823B1 (it) Composizioni farmaceutiche a base di proteine.
IT238518Y1 (it) Base per sedie,poltroncine o simili
IT8605138A1 (it) Dispositivo di supporto ad altezza regolabile particolarmente per sedie, poltrone, sgabelli e simili
IT1191390B (it) Dispositivo di supporto ad altezza regolabile particolarmente per sedie,poltrone,sgabelli e simili
IT8606950V0 (it) Dispositivo di supporto ad altezza regolabile particolarmente per sedie, poltrone, sgabelli e simili.
KR970004062U (ko) 상·하 높낮이 조정이 자유로운 등받이 의자의 베개
IT9033507V0 (it) Lettino con materasso basculabile, in particolare per uso medico, in saloni di estetica o simili
IT8620976A1 (it) Composizione farmaceutica a base di n-acil-fosfatidiletanolammina, procedimento per la preparazione della stessa, specialita' farmaceutica e uso della stessa
GB9718415D0 (en) Formulation